You just read:

RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

News provided by

RegeneRx Biopharmaceuticals, Inc.

Sep 21, 2015, 07:41 ET